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Abstract
Introduction: Glucocorticoids represent the therapy of choice for active and moderate-to-severe Graves' orbitopathy (GO). In some patients, 
rituximab, a monoclonal antibody against the cluster of differentiation (CD) 20 receptor of B-lymphocytes, can serve as a second-line or 
an alternative treatment. The effect of very low-dose of rituximab on the clinical activity of GO and corresponding clinical or laboratory 
changes is reported. 
Material and methods: Changes of Clinical Activity Score (CAS) for GO, proptosis, levels of thyroid-stimulating hormone receptor 
antibodies, and depletion of CD19+ and CD20+ B-lymphocytes were determined in ten patients (two men and eight women) with ac-
tive moderate-to-severe GO treated with a single 100-mg dose of rituximab. Correlations between differences of clinical and laboratory 
parameters were performed.
Results: A significant decrease of CAS was found during subsequent examinations compared to the baseline values. A significant depletion 
of CD19+ and CD20+ B-lymphocytes was detected after rituximab administration. Differences between follow-up and baseline levels of 
CD20+ positively correlated with differences in CAS after six (p < 0.05) and 12 months (p < 0.01). Differences in CD19+ levels correlated 
with differences in CAS after 12 months (p < 0.05) of the treatment. Two patients developed dysthyroid optic neuropathy (DON) requir-
ing orbital decompression. No other rituximab side effects were reported during the whole study duration.
Conclusions: A single very low-dose of rituximab appears to be very well tolerated and effective enough to reduce clinical activity in 
active moderate-to-severe GO patients without impending DON. (Endokrynol Pol 2017; 68 (5): 498–504)
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Streszczenie
Wstęp: Glikokortykoidy są leczeniem z wyboru w czynnej, umiarkowanej lub ciężkiej orbitopatii tarczycowej (Graves' orbitopathy, GO). 
U niektórych pacjentów jako leczenie drugiej linii lub leczenie alternatywne można zastosować rytuksymab, przeciwciało monoklonalne 
przeciw receptorowi kompleksu różnicowania (cluster of differentiation, CD) 20. W niniejszej pracy opisano wpływ bardzo małych dawek 
rytuksymabu na aktywność kliniczną GO i odpowiednie zmiany parametrów klinicznych i laboratoryjnych. 
Materiał i metody: U 10 chorych (2 mężczyzn i 8 kobiet) z czynną, umiarkowaną lub ciężką GO, którym podano pojedynczą dawkę 
100 mg rytuksymabu, oceniono zmiany oceny w skali aktywności klinicznej (Clinical Activity Score, CAS) orbitopatii tarczycowej, stopnia 
wytrzeszczu, stężenia przeciwciał przeciw receptorom hormonu tyreotropowego (thyroid-stimulating hormone, TSH) oraz liczby limfocytów 
B typu CD19+ i CD20+. Zbadano korelacje między zmianami parametrów klinicznych i laboratoryjnych.
Wyniki: W kolejnych badaniach stwierdzono zmniejszenie aktywności choroby ocenianej w skali CAS w porównaniu z wartościami 
wyjściowymi. Po podaniu rytuksymabu zaobserwowano zmniejszenie liczby limfocytów B typu CD19+ i CD20+. Różnice między liczbą 
limfocytów CD20+ podczas kolejnych wizyt kontrolnych a wartością wyjściową korelowały dodatnio z różnicami wartości wskaźnika 
CAS po 6 (p < 0,05) i 12 miesiącach (p < 0,01). Różnice w liczbie limfocytów CD19+ korelowały z różnicami wartości wskaźnika CAS po 
12 miesiącach (p < 0,05). U 2 chorych rozwinęła się neuropatia nerwu wzrokowego w przebiegu orbitopatii tarczycowej (dysthyroid optic 
neuropathy, DON) wymagająca dekompresji oczodołu. Nie stwierdzono innych działań niepożądanych rytuksymabu w trakcie badania.
Wnioski: Pojedyncza bardzo mała dawka rytuksymabu była bardzo dobrze tolerowana przez chorych i wystarczająco skuteczna 
w zmniejszaniu aktywności klinicznej choroby u pacjentów z czynną, umiarkowaną lub ciężką GO bez zagrażającej DON. (Endokrynol 
Pol 2017; 68 (5): 498–504)
Słowa kluczowe: orbitopatia tarczycowa, rytuksymab, skala aktywności klinicznej, tarczyca, neuropatia nerwu wzrokowego w przebiegi 
orbitopatii tarczycowej
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Introduction
Graves' orbitopathy (GO) is an autoimmune disorder 
of the orbital tissues that develops in 25–50% patients 
with Graves' disease [1, 2]. It may also occur in patients 
without any current or prior hyperthyroidism (euthy-
roid or ophthalmic Graves’ disease) or in hypothyroid 
patients due to chronic autoimmune thyroiditis [3]. GO 
is an inflammatory process characterised by oedema 
and inflammation of the extraocular muscles and an 
increase in orbital connective tissue and fat resulting 
in periorbital and conjunctival oedema, chemosis, lid 
retraction, exophthalmos, and dysmotility of eye mus-
cles, accompanied by spontaneous retrobulbar pain, 
pain on eye movement, watery and burning eyes, 
and/or diplopia [1, 2, 4]. Severe GO leads to exposure 
keratopathy and compressive optic neuropathy (dys-
thyroid optic neuropathy — DON), which may cause 
visual loss [1, 4, 5].
Although during recent years researchers have 
provided interesting data on the aetiology and patho-
genesis leading to development of GO, the exact 
pathological mechanism still remains unclear. Some 
risk factors were identified. Modifiable factors include 
smoking, thyroid dysfunction, radioiodine treatment 
for hyperthyroidism, and high thyroid-stimulating 
hormone (TSH) receptor antibody levels. Genetics, 
age, and gender are non-modifiable factors [1, 2, 6]. 
Shared thyroid and orbital antigens play an important 
role in the development of autoimmune process. Au-
toimmunity is probably triggered by recognition of the 
TSH receptor (TSH-R) expressed by fibroblasts and adi-
pocytes after their differentiation from preadipocytes 
[1, 2, 6]. Type I insulin-like growth factor receptor, an-
other antigen presented by orbital fibroblasts, and T and 
B lymphocytes, may also be involved in the initiation 
or maintenance of orbital autoimmunity [1, 2, 6]. After 
recognition of autoantigens, a number of reactions oc-
cur leading to proliferation of orbital fibroblasts, differ-
entiation of preadipocytes into adipocytes, production 
of autoantibodies, secretion of cytokines, infiltration of 
extraocular muscles, and increased secretion of glycosa-
minoglycans [2].
High-dose systemic glucocorticoids are currently the 
first-line treatment for active and moderate-to-severe 
GO [7]. More recent studies suggest that pulsed intrave-
nous methylprednisolone is more effective and has an 
improved side-effect profile compared to high-dose oral 
prednisone [7, 8]. This therapy is effective in 70–80% of 
patients, compared to 50% in those treated orally [2, 4, 7]. 
However, a significant proportion of them (20–30%) 
do not respond to glucocorticoids, and furthermore 
approximately 10–20% of all treated patients relapse 
after therapy withdrawal [8]. For these reasons, novel 
immunosuppressive agents targeting other pathogenic 
mechanisms have been introduced for GO treatment. 
Among them, rituximab has received particular atten-
tion in the last few years. Rituximab is a monoclonal 
antibody targeting the cluster of differentiation (CD) 
20 transmembrane antigen expressed by pre-B and 
mature B lymphocytes, but not by stem cells or plasma 
cells [9]. Its main effect is to deplete CD20-positive 
B-cells. Because plasma cells are not affected, antibody 
production is usually maintained. Immunosuppressive 
action of rituximab is probably mediated by the reduced 
activity of B cells as antigen-presenting cells and the 
decreased production of inflammatory cytokines. 
A potential indirect blockade of pathogenic autoan-
tibody generation is also suggested [8, 9]. Standard 
rituximab GO treatment regimen is usually 1000 mg 
intravenously twice at two-week intervals. However, 
a single 500 mg dose had a similar effect on GO clinical 
activity [10]. Moreover, Salvi M et al. demonstrated the 
effect of 100 mg rituximab on peripheral B-cell depletion 
and subsequent induction of GO long-term remission 
in two patients who did not receive a full dose due to 
an infusion reaction (progression of orbital soft tissue 
swelling) [11]. 
The aim of this paper is to report clinical and im-
munological changes in patients with active moderate-
to-severe GO, who were treated with very low-dose 
rituximab. 
Material and methods
The group consisted of ten Caucasian individuals (two 
men and eight women; three smokers and seven non-
-smokers; age range 27–74 years, average age 49.3 ± 
13.4 years), affected with active GO (GO duration 8.9 
± 5.7 months), defined by a clinical activity score (CAS 
= number of positive signs: spontaneous retrobulbar 
pain; pain on attempted up or down gaze; redness 
of the eyelids; redness of the conjunctiva; swelling of 
the eyelids; inflammation of the caruncle and/or plica; 
conjunctival oedema) ≥ 3 [3, 12], and of moderate- 
-to-severe degree, as defined by EUGOGO severity 
assessment (patients without sight-threatening GO 
and with two or more of the following: lid retraction 
≥ 2 mm, moderate or severe soft-tissue involvement, 
or exophthalmos ≥ 3 mm above normal for race and 
gender, no or intermittent diplopia and corneal expo-
sure responsive to lubricants) [3]. Six patients were after 
total thyroidectomy, and three were after radioiodine 
therapy. Thyroid function tests were normal in all of 
them. Patients signed informed consent forms ap-
proved by the institutional Ethics Committee of the 
Medical Faculty and University Hospital Olomouc. 
They were treated by rituximab in the period from 
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July 2013 to April 2015, and all of them were regularly 
checked for at least a year. 
Indications for rituximab administration were: 
persistently high GO activity (n = 4) or its reactivation 
(n = 3) after previous treatment by pulsed intravenous 
methylprednisolone (average previous cumulative 
dose of methylprednisolone was 7.3 ± 1.9 g) or con-
traindications for this therapy (n = 3). Intravenous 
application of 100 mg rituximab dose lasted for two 
hours. Infusion reaction to rituximab application was 
prevented by administration of methylprednisolone 
(100 mg), paracetamol (500 mg), and bisulepine (2 mg) 
before and by administration of paracetamol (500 mg) 
and bisulepine (2 mg) after the infusion.
Complete ophthalmological assessment (including 
visual acuity, evaluation of adnexa and eyelids, slit-lamp 
evaluation of anterior segment, fundus evaluation by 
indirect ophthalmoscopy, Hertel measurement, and 
ultrasound measurement of extraocular muscle thick-
ness) was made before rituximab administration and 
after one, six, and 12 months, respectively. The effect 
of therapy was monitored by assessment of CAS and 
by exophthalmos examination. Grade of proptosis was 
measured by Hertel exophthalmometer (taken from the 
lateral orbital rim to the corneal apex in millimetres for 
each eye and then average value calculated from both 
eyes).
The effect of rituximab on lymphocyte subpopula-
tions was analysed with a standard antibody panel for 
CD20+ and CD19+ subpopulations at baseline and 
after one month. TSH-R antibodies (TRAbs) were mea-
sured as TSH-R binding inhibitory immunoglobulins 
using a third-generation assay at baseline and after 
six and 12 months. Differences between baseline and 
follow-up levels of laboratory markers were calculated 
and correlated with differences in CAS and average 
proptosis.
Statistical analyses were performed using SPSS for 
Windows version 12.0 (Chicago, IL, USA). Parameters 
with normal distribution (normality was tested with 
Kolmogorov-Smirnov test) were expressed as mean ± 
SD, parameters with skewed distribution as median 
(first to third quartile of values). Differences in values 
of repeated measurements were analysed by Wilcoxon 
test. Spearman’s rank correlation analysis tested univa-
riate correlations between parameters. Probability values 
of p < 0.05 were considered as statistically significant. 
Results 
CAS improved in most patients after one month, and 
the improvement continued (Fig. 1). One patient after 
initial regression of disease activity suffered from late 
partial GO reactivation (CAS increased to 3.0 a year after 
rituximab administration) probably due to smoking re-
sumption. This patient was then successfully treated by 
a low-dose of oral prednisone, and during three months 
CAS decreased to 0. In the further observation we did 
not register any disease reactivation in any treated 
patient until submission of this paper.
Two patients developed DON requiring orbital de-
compression (during the first and fourth month after 
rituximab therapy). Both were corticoid-resistant and 
were excluded from the subsequent statistical evalua-
tion. Elective orbital decompression was also performed 
in one patient later (at 17th month after therapy) during 
Figure 1. Changes in clinical activity score (CAS) in individual patients
Rycina 1. Zmiany skali aktywności klinicznej (CAS) u pacjenta
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inactive phase of GO for exophthalmos with intermittent 
spontaneous eyeball subluxation. We did not encounter 
any other clinical or laboratory side effects of 100 mg 
rituximab treatment during the whole study duration.
Table I shows the clinical and laboratory parameters 
before and after administration of rituximab. There was 
a significant CAS decrease within one month and then 
within six and 12 months compared to the baseline va-
lues. A significant depletion was detected in CD19+ and 
CD20+ B-lymphocytes after rituximab administration. 
There was also a significant decrease of TRAbs within 
six and 12 months compared to baseline values. A mild 
proptosis decrease was observed up to 12 months after 
the treatment.
Further statistical evaluation of monitored param-
eters and their relationships is shown in Table II. Differ-
ences between follow-up and baseline levels of CD20+ 
cells (ΔCD20+) positively correlated with differences in 
CAS after six months (ΔCAS 0–6, p < 0.05) and after 12 
months (ΔCAS 0–12, p < 0.01) following rituximab ad-
ministration. Difference between follow-up and baseline 
levels of CD19+ cells (ΔCD19+) positively correlated 
with differences in CAS after 12 months (CAS 0–12, 
p < 0.05) only. There were no other significant correlations.
Discussion
Administration of a very low-dose of rituximab resulted 
in a significant depletion of B-cells and a suppression 
of GO clinical activity. Treatment was long-term effec-
tive and safe.
The first case report on successful treatment of 
moderate-to-severe GO with rituximab was published 
in 2006 [13]. Since that time several mostly smaller, open, 
and non-controlled studies have been performed with 
promising findings [7, 14, 15]. However, two recent 
randomised controlled trials published in the last year 
revealed rather different results [10, 16]. 
Table II. Correlations between differences of clinical and laboratory parameters
Tabela II. Korelacje między różnicami w wartościach parametrów klinicznych i laboratoryjnych
ΔCD19+ ΔCD20+ ΔTRAbs 0–6 ΔTRAbs 0–12
ΔCAS 0–1 n.s. n.s. n.s. n.s.
ΔCAS 0–6 ρ = 0.93, p < 0.05 ρ = 0.88, p < 0.05 n.s. n.s.
ΔCAS 0–12 n.s. ρ = 0.78, p<0.05 n.s. n.s.
ΔAP 0–1 n.s. n.s. n.s. n.s.
ΔAP 0–6 n.s. n.s. n.s. n.s.
ΔAP 0–12 n.s. n.s. n.s. n.s.
ΔTRAbs 0–6 n.s. n.s. ρ = 1 n.s.
ΔTRAbs 0–12 n.s. n.s. n.s. ρ = 1
ΔCAS — CAS at baseline – CAS after one (0–1), six (0–6), or 12 (0–12) months, ΔAP — AP at baseline – AP after one (0–1), six (0–6), or 12 (0–12) months, ΔCD19+ 
— CD19+ at baseline – CD19+ after one month, ΔCD20+ — CD20+ at baseline – CD20+ after one month, ΔTRAbs — TRAbs at baseline – TRAbs after six (0–6), 
or 12 (0–12) months of rituximab administration 
CAS — clinical activity score, AP — average proptosis, CD19+ — proportion of lymphocyte with CD (cluster of differentiation) marker 19, CD20+ — proportion of 
lymphocyte with CD marker 20, TRAbs — thyroid-stimulating hormone receptor antibodies 
ρ (rho) — Spearman’s correlation coefficient, p — level of statistical signification, n.s. — not significant
Table I. Clinical and laboratory parameters at baseline and after rituximab administration
Tabela I. Parametry kliniczne i laboratoryjne na początku badania i po podaniu rytuksymabu
At baseline At month one
after rituximab
At month six
after rituximab
At month 12
after rituximab
CAS 3.6 ± 0.9 2.0 ± 0.8** 0.8 ± 0.4** 0.4 ± 0.9**
AP (mm) 22.3 ± 1.6 21.8 ± 1.6 21.5 ± 1.7 21.1 ± 1.8*
CD19+ (%) 4.04 ± 1.67 0.22 ± 0.20* – –
CD20+ (%) 4.23 ± 1.59 0.03 ± 0.07* – –
TRAbs (IU/L) 5.7 (1.1–41.0) – 1.6 (1.0–6.9)* 2.1 (0.2–5.7)*
CAS — clinical activity score, AP — average proptosis, CD19+ — proportion of lymphocyte with CD (cluster of differentiation) marker 19, CD20+ — proportion of 
lymphocyte with CD marker 20, TRAbs — thyroid-stimulating hormone receptor antibodies 
Values are expressed as mean ± standard deviation, for parameters with skewed distribution (TRAbs) as median (25th and 75th percentiles) 
* ~ p < 0.05, ** ~ p < 0.01 statistical significance level (comparison with baseline values, Wilcoxon test)
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Salvi et al. confirmed a better therapeutic outcome 
of rituximab (2 × 1000 mg) in active moderate-to-severe 
GO, when compared with intravenous methylpredniso-
lone, even after a lower rituximab dose (1 × 500 mg) [10]. 
CAS decreased in both therapeutic modes but more 
after rituximab (100 vs. 69% after intravenous meth-
ylprednisolone). Moreover, the patients treated with 
rituximab showed better eye motility outcome, vi-
sual functioning of the quality of life assessment, and 
a reduced number of surgical procedures compared to 
patients treated with glucocorticoids. GO reactivation 
never occurred after rituximab, although it did in 31% 
of patients after intravenous methylprednisolone [10].
By contrast, Stan et al. did not find any significant 
reduction in CAS assessed as a continuum and sepa-
rately as improvement by ≥ 2 points at 24 weeks after 
two rituximab infusions (1000 mg each) compared to 
placebo [16]. CAS at 24 and 52 weeks improved from 
baseline in most patients similarly in both groups. In 
addition, there were no differences in the secondary 
assessments that included multiple quantitative meas-
ures of disease severity, the NOSPECS classification [7], 
a composite assessment of treatment failure, and 
a quality of life questionnaire [16]. 
These discrepant results may be elucidated by the 
differences in study population, degree of GO activity, 
and disease duration [7, 8]. Another explanation for 
the same CAS improvement in both groups (rituximab 
versus placebo) in the latter study could be the effect 
of the natural course of GO as a self-limiting autoim-
mune disease. However, several case report studies 
demonstrated the relationship between rituximab 
administration and a decrease of inflammatory orbital 
infiltration, particularly complete depletion of CD20+ 
lymphocytes [11, 14, 17]. Significant changes of 99mTc-
labelled diethylenetriaminepentaacetic acid orbital 
uptake and of T2 relaxation times of extraocular muscles 
on magnetic resonance imaging showing the effect of 
rituximab treatment for GO were also reported [18]. 
Positive correlations between CAS improvement and 
decrease of CD20+ and CD19+ lymphocytes and lack 
of a correlation between CAS improvement and TRAbs 
decrease in our study group favour the therapeutic ef-
fect of rituximab over the natural course of disease on 
GO clinical activity.
The question of the appropriate dose for therapy 
of active GO remains unanswered. Results of recent 
studies showed that rituximab may be effective in 
patients with GO even at lower doses than currently 
recommended in autoimmune rheumatic diseases [8]. 
Mitchell et al. used rituximab to treat eight patients 
with active, steroid-refractory GO and one with inac-
tive disease. Although three patients received the full 
dose of 1000 mg twice, six received only 500 mg twice, 
and one of them 500 mg three times, until a peripheral 
B-cell depletion was attained. Reduction of CAS was 
seen in all cases [19]. In the previously mentioned study 
Salvi et al. found CAS decrease in moderate-severe GO 
independent of the rituximab dose (1000 or 500 mg) [9]. 
Our findings focused on 100 mg of rituximab as the suf-
ficient dose to induce a significant B-lymphocyte deple-
tion and a reduction of CAS. Similar results were also 
presented by Vannuchi et al. [20]; a single very low-dose 
of rituximab (100 mg) was effective in inactivating GO 
in 12/14 patients (85.7%) with short disease duration. 
As well as economic benefit, a lower dose of rituximab 
should be connected with lower frequency of dose-
dependent side effects. Infusion-related reactions are 
the most frequently reported short-term side effects of 
rituximab that may occur in about 10–30% of patients at 
its first infusion [7]. Rarely, transient but significant peri-
orbital oedema and inflammation may also occur [11]. 
We did not register any of them. 
Duration of action of rituximab treatment may be 
potentially affected by its dose. However, similar dura-
tion of CD20+ and CD19+ peripheral cell depletion 
was observed in two patients after receiving 100 mg 
of rituximab, as in 10 patients treated with two cycles 
of 1000 mg of rituximab for active GO [11]. Treatment 
response may, of course, be individual, but the mean 
reported duration of peripheral B-cell depletion in 
patients with GO treated by rituximab was 16.7 ± 2.1 
weeks [21]. Salvi et al. did not observe any GO reacti-
vation after higher dose of rituximab [10]. One of our 
patients suffered from a late partial reactivation a year 
after the treatment. We suppose that it was probably 
due to the patient’s non-compliance (smoking resump-
tion) and was not related to the rituximab dose. Still, it 
is not known if very low-dose of rituximab may modify 
the natural course of disease, as has been observed with 
higher therapeutic doses [8].
Two patients developed DON requiring orbital 
decompression (within one month and four months 
after rituximab). One of them exhibited initial signs 
of DON at the time of treatment. They both were 
glucocorticoid-resistant, and rituximab represented the 
second-line therapeutic option. Surgical decompres-
sion led to a complete recovery [22]. Rituximab was 
successfully used in patients with DON [19, 23, 24], 
but available evidence from one of the randomised 
studies [16], as well as a case report of a patient with 
glucocorticoid-resistant GO [25], suggests that progres-
sion of DON may occur after rituximab, even after its 
higher doses. Vannuchi et al. reported two patients 
not responding to a single very low-dose of rituximab 
(100 mg), who developed DON treated with a surgi-
cal orbital decompression [20]. Based on the above, 
recent ETA/EUGOGO guidelines do not recommend 
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rituximab for patients with impending DON or long 
duration of disease [7].
Contrary to GO activity, the severity of GO evalu-
ated by proptosis measurement changed much less 
during the treatment and did not correlate with pe-
ripheral B-cell depletion in our study group. Proptosis 
or NOSPECS improvement has been seen in some 
open studies and in several case reports [11, 13, 14, 19]. 
However, results from randomised trials [10, 16] and 
other retrospective, interventional case series [23] 
did not show significant effect of rituximab (even in 
higher doses) on changes of these GO severity mark-
ers. Salvi et al. found better eye motility outcome and 
a reduced number of surgical procedures in patients 
treated with rituximab compared to patients treated 
with glucocorticoids [10]. However, Stan et al. docu-
mented no differences between treated and placebo 
groups in changes of proptosis, diplopia, lid fissure 
width, lagophthalmos, or NOPSPECS score improve-
ment [16]. GO severity improvement is long lasting 
and there are other factors (genetic factors, ancestry, 
gender, thyroid function, local anatomical conditions, 
smoking, radioactive iodine therapy, etc.), which can 
modify this process [26].
We observed significant decrease of TRAbs during 
the treatment, but the changes of TRAbs did not cor-
relate with changes of clinical activity or with B-cell 
depletion in our study. There is inconsistent evidence 
on the effect of rituximab on TRAbs circulating an-
tibodies in other studies [15]. A significant decrease 
of TRAbs was observed during the treatment, but 
mostly not related to B-cell depletion [14, 19, 21, 27]. 
El Fassi et al. reported that rituximab may favour-
ably affect Graves’ disease remission by distinctively 
affecting production of the thyroid-stimulating au-
toantibodies (TSAbs) in a small group of patients [28]. 
We were not able to measure this subpopulation of 
TRAbs. However, Vannucchi et al. did not confirm 
previously suggested distinct effect of rituximab on 
serum TSAbs, also measured as immunoglobulin-
stimulation of cAMP by TSH-R transfected Chinese 
hamster ovary cells [21]. Most findings suggest that 
rituximab does not have an effect on either thyroid 
or orbital autoantibody production, while acting in a 
distinct way on the compartments of lymphocytic in-
filtrates of the thyroid and the orbit tissues [14, 21, 23]. 
Generally, its rapid therapeutic effect observed in 
autoimmune diseases argues against an antibody-me-
diated action [21]. Also, TRAbs levels decreased dur-
ing a study comparing patients treated by rituximab 
or by placebo similarly in both patient groups [16]. 
So, the decrease of circulating TRAbs levels may 
reflect the natural course of the GO rather than the 
effect of rituximab treatment.
Our study has several limitations. This was an open, 
non-controlled, non-randomised study. The number 
of patients was small. There were 80% of women and 
only 20% of men. Heterogeneity of the treated group 
was given also by age variance, duration of GO, and its 
previous treatment. There were seven glucocorticoid-
resistant patients. Three subjects were naive to gluco-
corticoid treatment. Due to low disease incidence, we 
can find similar limitations also in some previously 
published studies. Multicentre trials recruiting greater 
numbers of patients seems to be an adequate solution 
for this problem.
Conclusions
Although reported findings were not derived from a 
randomised, controlled, large trial, some important 
conclusions can still be drawn. A single very low-dose 
of rituximab appears to be very well tolerated and ef-
fective enough to reduce clinical activity in active and 
moderate-to-severe GO patients without impending 
DON. However, larger, randomised, controlled trials 
will be necessary to confirm these results and find the 
optimal dose of rituximab in various groups of GO 
patients.
Supported by MH CZ DRO (FNOl, 00098892) — 87–62.
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